TREVENA INC
DelistedCIK 1429560fmd_03WPCFC3413DQGXGX6Q4PQCAAEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2024, 47 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 6 | 4 | 0 | 6 | 0 | 3 | 1 | – | – |
| Cost of revenue | – | – | – | – | – | – | 0 | 1 | 3 | 2 |
| Gross profit | – | – | – | – | – | – | 3 | (0) | – | – |
| Research and development | 41 | 44 | 90 | 49 | 16 | 13 | 13 | 13 | 18 | 16 |
| Total operating expenses | 50 | 57 | 106 | 70 | 36 | 27 | – | – | – | – |
| Operating income | (50) | (51) | (102) | (70) | (30) | (27) | (29) | (52) | (56) | (35) |
| Interest expense | 0 | 0 | 2 | 3 | 2 | 1 | 0 | 0 | 1 | 4 |
| Interest and investment income | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | 0 | 0 | (1) | (1) | 0 | 2 | 0 | 0 | 3 | (5) |
| Income before taxes | – | – | (103) | (72) | (30) | (25) | (29) | (52) | – | – |
| Income tax expense | – | – | – | – | 1 | – | 0 | – | – | 0 |
| Net income from continuing operations | – | – | – | – | (31) | – | (29) | – | – | – |
| Net income | (50) | (51) | (103) | (72) | (31) | (25) | (29) | (52) | (54) | (40) |
| Net income to common shareholders | (50) | (51) | (103) | (72) | (31) | (25) | (29) | (52) | (54) | (40) |